Mutational analysis of the PRL receptor gene in human breast tumors with differential PRL receptor protein expression.

PRL is a major growth and differentiating hormone in the human breast, with activation of the PRL-PRL receptor complex increasingly recognized as an important mechanism in the induction and progression of mammary tumors. Although constitutive activation of various hormone and growth factor receptors is newly recognized as a common cause of tumor development, the PRL receptor gene has not been analyzed for similar aberrations in breast and other tumors. Therefore, using bacterial artificial chromosomes containing the PRL receptor gene and intron-spanning PCR, we determined the exon-surrounding intron sequences providing primers for the first analysis of the entire coding region of the human PRL receptor gene. We examined the presence of PRL receptor in 41 breast tumors by immunohistochemistry and attempted a correlation of its expression to pathological grading of the disease. Then tumor cells were isolated by laser capture microdissection to examine DNA from 30 patients for PRL receptor mutations. The PRL receptor immunoreactive score did not correlate to the tumor size, histopathological grading, age, or family history of patients. PRL receptor immunoreactivity was predominantly found in steroid hormone receptor-positive tumors, but without overall correlation of immunoreactive score. In both PRL receptor-positive and PRL receptor- negative breast cancer cells, direct sequencing of the coding sequence of the PRL receptor gene did not detect any somatic or hereditary gene aberrations. In conclusion, PRL receptor mutations do not appear to be common in human breast cancer, suggesting that constitutive activation of the PRL receptor can be excluded as a major cause of mammary tumor genesis. The molecular structure of the PRL receptor seems to remain intact in tumor tissue, and systemic and local production of PRL may participate in tumor cell growth and proliferation through functional receptors.

[1]  C. Clevenger,et al.  Functional Characterization of the Intermediate Isoform of the Human Prolactin Receptor* , 1999, The Journal of Biological Chemistry.

[2]  P. Ingleton,et al.  Dissociation of Janus Kinase 2 and Signal Transducer and Activator of Transcription 5 Activation after Treatment of Nb2 Cells with a Molecular Mimic of Phosphorylated Prolactin1. , 1999, Endocrinology.

[3]  Kirschner Ls,et al.  Large-scale preparation of sequence-ready bacterial artificial chromosome DNA using QIAGEN columns. , 1999 .

[4]  P. Kelly,et al.  Should prolactin be reconsidered as a therapeutic target in human breast cancer? , 1999, Molecular and Cellular Endocrinology.

[5]  Y. Bignon,et al.  Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. , 1999, Biochemical and biophysical research communications.

[6]  S. Anderson,et al.  Constitutive Activation of the Prolactin Receptor Results in the Induction of Growth Factor-independent Proliferation and Constitutive Activation of Signaling Molecules* , 1999, The Journal of Biological Chemistry.

[7]  J. Manson,et al.  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[8]  S. Amselem,et al.  Defects of the growth hormonereceptor and their clinical implications , 1999 .

[9]  J. Meng,et al.  The human prolactin receptor gene structure and alternative promoter utilization: the generic promoter hPIII and a novel human promoter hP(N). , 1999, The Journal of clinical endocrinology and metabolism.

[10]  B. Teh,et al.  The genetic basis of breast cancer and its clinical implications. , 1999, The Australian and New Zealand journal of surgery.

[11]  Hindle Wh Hormone alterations in breast cancer: examining the hypotheses. , 1999 .

[12]  S. Amselem,et al.  Defects of the growth hormone receptor and their clinical implications. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[13]  W. Hindle Hormone alterations in breast cancer: examining the hypotheses. , 1999, Medscape women's health.

[14]  C. Stratakis,et al.  Large-scale preparation of sequence-ready bacterial artificial chromosome DNA using QIAGEN columns. , 1999, BioTechniques.

[15]  P. Ingleton,et al.  Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. , 1999, Endocrinology.

[16]  W. Scherbaum,et al.  Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. , 1998, The Journal of clinical endocrinology and metabolism.

[17]  K. Horwitz,et al.  Convergence of Progesterone with Growth Factor and Cytokine Signaling in Breast Cancer , 1998, The Journal of Biological Chemistry.

[18]  T. Fujikawa,et al.  Cooperative and differential effects of estrogen, prolactin, 22K and 20K human growth hormones on cyclin D1/PRAD1 gene expression in T‐47D human breast cancer cells , 1998, Biochemistry and molecular biology international.

[19]  C. Brooks,et al.  Phosphorylation of bovine prolactin eliminates luteotropic activity in the rat. , 1998, Life sciences.

[20]  B. Vonderhaar Prolactin: the forgotten hormone of human breast cancer. , 1998, Pharmacology & therapeutics.

[21]  P. Kelly,et al.  Differential expression of prolactin receptor (PRLR) in normal and tumorous adrenal tissues: separation of cellular endocrine compartments by laser capture microdissection (LCM). , 1998, Endocrine research.

[22]  P. Kelly,et al.  Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. , 1998, Endocrine reviews.

[23]  M. Waters,et al.  Cellular expression of growth hormone and prolactin receptors in human breast disorders , 1998, International journal of cancer.

[24]  P. Kelly,et al.  Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  C. Ohlsson,et al.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. , 1997, The Journal of clinical investigation.

[26]  C. Powell,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Prolactin and Its Receptor in Human Breast Carcinoma* , 2022 .

[27]  Robert F. Bonner,et al.  Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.

[28]  R. Blamey,et al.  Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. , 1997, The Journal of clinical endocrinology and metabolism.

[29]  P. Kelly,et al.  Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation. , 1997, Journal of cell science.

[30]  R. D'Andrea,et al.  Activating mutations in cytokine receptors: implications for receptor function and role in disease. , 1997, Blood.

[31]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[32]  P. Chikhlikar,et al.  Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators , 1996, Journal of surgical oncology.

[33]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[34]  R. Gelber,et al.  IX. International consensus conference on primary treatment of breast cancer. , 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[35]  C. Watson,et al.  Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. , 1995, British Journal of Cancer.

[36]  J. Leonardelli,et al.  [Immunocytochemical analysis of human prolactin receptors using anti-idiotypic antibodies in human breast cancer]. , 1995, Annales de pathologie.

[37]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[38]  B. Vonderhaar,et al.  Characterization of a monoclonal antibody against human prolactin receptors , 1993, International journal of cancer.

[39]  T. Hoffmann,et al.  Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance , 1993, Journal of endocrinological investigation.

[40]  H. LaVoie,et al.  Glucocorticoid-Prolactin Interactions in Nb2 Lymphoma Cells: Antiproliferative versus Anticytolytic Effects , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[41]  R. Sutherland,et al.  Mechanisms of prolactin receptor regulation in mammary gland , 1993, Molecular and Cellular Endocrinology.

[42]  Phillips Rd Molecular biology of growth hormone receptor dysfunction. , 1992 .

[43]  B L De Stavola,et al.  Relationship of blood prolactin levels and the risk of subsequent breast cancer. , 1992, International journal of epidemiology.

[44]  J. Phillips Molecular biology of growth hormone receptor dysfunction. , 1992, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[45]  J. Bonneterre,et al.  Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  D. Ingram,et al.  Prolactin and breast cancer risk , 1990, The Medical journal of Australia.

[47]  S. de Placido,et al.  Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. , 1990, British Journal of Cancer.

[48]  R. Callahan,et al.  Mutations in human breast cancer: an overview. , 1989, Journal of the National Cancer Institute.

[49]  S. Tandon,et al.  Highly specific sites of prolactin binding in benign and malignant breast tissue. , 1989, Indian journal of experimental biology.

[50]  P. Kelly,et al.  Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. , 1989, Molecular endocrinology.

[51]  L. J. Lewis,et al.  Two forms of glycosylated human prolactin have different pigeon crop sac-stimulating activities. , 1989, Endocrinology.

[52]  W. Lotze [The epidemiology and etiology of breast cancer]. , 1989, Zentralblatt fur Gynakologie.

[53]  M. Eigenbrodt,et al.  Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. , 1988, The American journal of pathology.

[54]  A. Schally,et al.  Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. , 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[55]  B. Mobbs,et al.  Use of an enzymeimmunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer. , 1987, Journal of steroid biochemistry.

[56]  H. Vorherr Endocrinology of breast cancer. , 1987, Maturitas.

[57]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[58]  H. Imura,et al.  Prognostic value of estrogen and prolactin receptor analysis in human breast cancer. , 1985, Japanese journal of cancer research : Gann.

[59]  H. Rauschecker,et al.  Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer , 1984, International journal of cancer.

[60]  P. Kao,et al.  Demonstration of biological activity of prolactin molecular weight variants in human sera. , 1984, The Journal of clinical endocrinology and metabolism.

[61]  L. Murphy,et al.  Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. , 1984, Cancer research.

[62]  R. Walker,et al.  The localization of prolactin binding sites in human breast tissue , 1983, International journal of cancer.

[63]  J. Bonneterre,et al.  Prolactin receptors in human breast cancer. , 1982, European journal of cancer & clinical oncology.

[64]  R. Hähnel,et al.  Prolactin receptors in human breast carcinoma , 1979, Cancer.

[65]  H. Friesen,et al.  Hormone binding by human mammary carcinoma. , 1977, Cancer research.

[66]  H. Nagasawa,et al.  Prolactin and murine mammary tumorigenesis: a review. , 1977, Cancer research.